ICCC · Immucell Corp /De/
$10.22
+0.09 (+0.89%)
At close · Aug 20
Market Cap
$92.00M
Shares
9.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.13
Open$9.76
Day$9.61–10.38
52W close$4.56–11.72
Avg vol 30d31K
Short int18K · 0.2% float · 1.0d
Short vol47%
Last earningsJul 9, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Sep 28, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
−4%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+55%
trailing
YTD return
+65%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.19% of float · ▲ +25.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
43%
contracting
EPS growth
+54%
Y/Y
Free cash flow
$1.2M
Valuation
P/E 144.7
rich
Balance sheet
$5.3M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
first half of 2027
Freeze-drying capacity expansion investment (first phase)
$3.5M
approximately six months (following first phase)
First Defense® colostrum liquid processing capacity investment (
$4.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.19% of float · ▲ +25.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $10 · 78%
Range high $12
vs 200-day avg +30%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.7M | three months ended June 30, 2026 | — |
| Domestic Sales | $16M | Six Months Ended June 30, 2026 | — |
| Dual-Force® and Other Sales | $4.8M | Six Months Ended June 30, 2026 | — |
| International Sales | $1.6M | Six Months Ended June 30, 2026 | — |
| Total Product Sales | $17.5M | Six Months Ended June 30, 2026 | — |
| Tri-Shield First Defense® Sales | $12.8M | Six Months Ended June 30, 2026 | — |
| EBITDA non-GAAP | $2.58M | Q1 2026 | — |
|
|
|||
| average monthly output | 380,000 | the year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICCC
this stock
Immucell Corp /De/
|
$92.00M | +64.7% | +51.6% | 144.7 | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +24.0% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +21.8% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +8.9% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +491.3% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICCC | -7.7% | -9.0% | +54.7% | -9.6% | +64.7% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -7.3% | -11.9% | +43.1% | -12.6% | +51.9% |
Key facts
CIK
811641
CUSIP
452525306
13F (30d)
27 filings
27 filers
Visit website
Investor relations